Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamrevlumab plus corticosteroids in ambulatory Duchenne muscular dystrophy
NL-OMON54230Phase 3Active, not recruiting
- Sponsor
- FibroGen
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing Pamrevlumab + systemic corticosteroid with Placebo + systemic corticosteroid (2 arms). Primary endpoint: Change in NorthStar Ambulatory Assessment total score. Started Mar 2022; status: active, not recruiting.
02
Drugs
pamrevlumab
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON54230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54230.